Thrombotic complications are a hallmark of antiphospholipid syndrome (APS). These
vascular–arterial, venous, and/or small vessel–complications are well described and known …

Warfarin, heparin, and/or antiplatelet drugs are the standard of care for aPL-positive
patients. Recent studies suggest novel approaches that target new coagulation and …

Objectives Thrombocytopenia, a frequent clinical manifestation in patients with APS, could
be an independent predictor of recurrent thrombotic, obstetric and severe extracriteria …

Antiphospholipid syndrome (APS) is an acquired autoimmune disease characterized by
thromboembolic events, pregnancy morbidity, and the presence of antiphospholipid (aPL) …

Women with persistently circulating antiphospholipid antibodies (aPL) have a higher
incidence of recurrent abortions, fetal losses, pre-eclampsia, and placental insufficiency …

Pathogenic antiphospholipid antibodies (aPL) are the driving factors of recurrent pregnancy
loss and thrombosis that characterize antiphospholipid syndrome (APS). Current evidence …

Antiphospholipid syndrome (APS) is a rare autoimmune disease of unknown etiology that
represents a leading cause of acquired thromboembolism and recurrent miscarriage. It is …

Antiphospholipid syndrome (APS) encompasses a wide spectrum of disease manifestations
that may prevail in the form of venous or arterial thrombosis or lead to pregnancy …

The antiphospholipid syndrome (APS) is characterized by the development of venous and/or
arterial thrombosis and pregnancy morbidity in patients with persistent antiphospholipid …

Antiphospholipid syndrome (APS) is a disorder with manifestations of venous or arterial
thrombosis or pregnancy loss associated with the persistent presence of antiphospholipid …